Article
Prognostic Value of Plasma hPG$_{80}$ (Circulating Progastrin) in Metastatic Renal Cell Carcinoma

Manish Kohli 1,*; Winston Tan 2; Bérengère Vire 3; Pierre Liaud 3; Méлина Blairvacq 3; Frederic Berthier 4; Daniel Rouison 4; George Garnier 5; Léa Payen 5; Thierry Cousin 6; Dominique Joubert 6 and Alexandre Prieur 6,*

1 Division of Oncology, Department of Medicine, Huntsman Cancer Institute, 2000 Circle of Hope Dr., Salt Lake City, UT 84112, USA
2 Division of Hematology-Oncology, Mayo Clinic, Jacksonville, FL 32224, USA; tan.winston@mayo.edu
3 Eurobiodev, 2040 Avenue du Père Soulas, 34000 Montpellier, France; b.vire@eurobiodev.com (B.V.); p.liaud@eurobiodev.com (P.L.); m.blairvacq@eurobiodev.com (M.B.)
4 Centre Hospitalier Princesse Grace, 1 Avenue Pasteur, Principauté de Monaco, 98000 Monaco, Monaco; frederic.berthier@chpg.mc (F.B.); daniel.rouison@chpg.mc (D.R.); georges.garnier@chpg.mc (G.G.)
5 Laboratoire de Biochimie et Biologie Moléculaire, CITOHL, Centre Hospitalier Lyon-Sud, 69310 Pierre-Bénite, France; lea.payen-gay@chu-lyon.fr
6 ECS-Progastrin, Chemin de la Meunière 12, 1008 Prilly, Switzerland; t.cousin@ecs-progastrin.com (T.C.); d.joubert@ecs-progastrin.com (D.J.)
* Correspondence: manish.kohli@hci.utah.edu (M.K.); a.prieur@ecs-progastrin.com (A.P.)

Simple Summary: Metastatic renal cell carcinoma (mRCC) accounts for one-third of all newly diagnosed renal cell cancers. A better understanding of the biology and molecular basis of disease progression has resulted in several drug targets being identified and led to approval of several new drugs for treating mRCC in the past decade. A growing need has emerged for identifying novel molecular tumor biology based and stage-specific prognostic and predictive biomarkers in mRCC reflector of biology beyond the currently available prognostic models which are solely based on clinical characteristics. We investigated hPG80 (circulating progastrin), which is associated with kidney cancer biology and found that hPG80 levels is both an independent prognostic marker in mRCC and also improves current clinical prognostic models. This will help stratify mRCC patients more accurately in future and improve the management of mRCC patients.

Abstract: Precise management of kidney cancer requires the identification of prognostic factors. hPG80 (circulating progastrin) is a tumor promoting peptide present in the blood of patients with various cancers, including renal cell carcinoma (RCC). In this study, we evaluated the prognostic value of plasma hPG80 in 143 prospectively collected patients with metastatic RCC (mRCC). The prognostic impact of hPG80 levels on overall survival (OS) in mRCC patients after controlling for hPG80 levels in non-cancer age matched controls was determined and compared to the International Metastatic Database Consortium (IMDC) risk model (good, intermediate, poor). ROC curves were used to evaluate the diagnostic accuracy of hPG80 using the area under the curve (AUC). Our results showed that plasma hPG80 was detected in 94% of mRCC patients. hPG80 levels displayed high predictive accuracy with an AUC of 0.93 when compared to 18–25 year old controls (12 versus 31.2 months, respectively; $p=0.0076$). Adding hPG80 levels (score of 1 for patients having hPG80 levels > 4.5 pM) to the six variables of the IMDC risk model showed a greater and significant difference in OS between the newly defined good-, intermediate- and poor-risk groups ($p=0.0003$ compared to $p=0.0076$). Finally, when patients with IMDC intermediate-risk group were further divided into two groups based on hPG80 levels within these subgroups, increased OS were observed in patients with low hPG80 levels (<4.5 pM). In conclusion, our data suggest that hPG80 could be used for prognosticating survival in mRCC alone or integrated to the IMDC score (by adding a variable to the IMDC score or by stratifying the IMDC risk groups), be a prognostic biomarker in mRCC patients.
Keywords: metastatic renal cell carcinoma (mRCC); hPG\textsubscript{80}; IMDC; blood-based prognostic biomarker; circulating progastrin

1. Introduction

Metastatic renal cell carcinoma (mRCC) accounts for one-third of 73,750 new RCC patients at initial presentation in the US [1] and 14,380 deaths are estimated in 2020 [2]. mRCC is a group of heterogeneous tumor types characterized by distinct biologic patterns and prognosis [3,4]. In the past 15 years, the introduction of targeted therapy, and more recently immunotherapy, have increased the therapeutic armamentarium available to treat metastatic stage and increased overall survival (OS) [5–7]. In parallel, major technological advances have led to a better understanding of the molecular basis of disease progression and the identification of several prognostic biomarkers [8–10]. However, well-validated prognostic biomarkers associated with tumor biology of metastatic kidney cancer stage are lacking.

Recent clinical trials have used the International Metastatic Database Consortium (IMDC) model for prognostication [11–13]. This model is based on six clinical variables as risk factors for short survival (time from diagnosis to initiation of therapy of less than 1 year, Karnofsky performance status of less than 80%, serum hemoglobin below the lower limit of normal and corrected calcium, neutrophil count, and platelet count greater than the upper limit of normal) and classify patients into good- (0 risk factor), intermediate- (1 or 2 risk factors) and poor-risk (≥3 risk factors) groups [14]. As a result, targeted therapeutics in metastatic RCC uses non-molecular based clinical prognostic variables for initiating novel drug interventions and combinations highlighting the need for enhancing prognostic markers in metastatic RCC [15,16].

We have reported previously [17] progastrin to be elevated in plasma of patients with metastatic kidney cancer. In physiology, progastrin is the precursor of gastrin synthetized by antrum G cells and processed into gastrin [18]. Progastrin does not accumulate in G cells, by contrast to G34-Gly and gastrin [19]. G34-Gly will generate gastrin upon full maturation. As a consequence, progastrin is barely detectable in the blood of healthy subjects even though few of them have been shown to be positive as observed the first time by Siddheshwar et al. [20]. However, in line with the demonstration of the expression of the \textit{GAST} gene, encoding progastrin, in colorectal tumors as well as other tumor types, high levels of hPG\textsubscript{80} (named as such when progastrin is released from tumor cells and detected in the blood) were reported in the blood of cancer patients [17,20,21]. Moreover, in addition to the fact that \textit{GAST} is a direct target of the ß-catenin/Tcf4 pathway, activated in many cancers, including RCC [22,23], a large body of literature supports the functional role of hPG\textsubscript{80} in tumorigenesis [21,24–28]. As a consequence, hPG\textsubscript{80} is an interesting indicator of tumor behavior/activity and may also represent a factor for aggressive biology and clinical outcomes.

In the present study, we determined the prognostic value of hPG\textsubscript{80} in clinically diagnosed metastatic RCC (mRCC) patients and examined whether hPG\textsubscript{80} might improve stratification of the currently used IMDC model to predict overall survival (OS).

2. Materials and Methods

2.1. Patients and Control Cohorts

Figure 1 illustrates the different cohorts used in this study to determine prognostic value of hPG\textsubscript{80} in metastatic RCC stage.
2.1.1. mRCC Patient Cohort

A large tertiary level, clinically annotated hospital registry with prospective and uniform blood/plasma collection from non-fasting metastatic kidney cancer patients between 5/2011 and 9/2013 and uniform sampling was used as has been previously described [29,30]. All patients \((n = 143)\) provided written informed consent for research at the time of their blood collection, in line with international regulations and ICH GCP (International Conference on Harmonization- Good Clinical Practice) and on an Institutional Review Board approved study protocol (Mayo Clinic IRB #11-005855 00). Of note, the majority of the patients had the blood draw close to the time of the diagnosis of metastatic disease, with a median value of 6 days (IQR: 0–117).

2.1.2. RCC Patient Cohort

Blood samples from non-fasting RCC patients \((n = 39)\) were obtained from Tissue For Research Ltd. (Spectrum Health System, Grand Rapids, Michigan, MI, USA).

2.1.3. Non-Cancer Age and Non Age Matched Control Cohorts

A young-aged cohort of plasma samples (18–25 years old) was obtained from non-fasting 137 healthy blood donors, from the French blood agency (Etablissement Français du Sang). This cohort was assumed to be at very low risk of cancer in order to maximize the likelihood of the control group being cancer-free [31]. A second, over 50 years old cohort of plasma samples (range 50–80 year old; median value 55 year old) was collected from fasting 252 healthy subjects, from the interim analysis from the PROCODE study (NCT03775473, https://clinicaltrials.gov/ct2/show/NCT03775473).

2.2. hPG\textsubscript{80} Level Measurements in the Blood Samples

The DxPG\textsubscript{80} test is an Enzyme-Linked Immunosorbent Assay (ELISA) for the quantitative measurement of human hPG\textsubscript{80} in EDTA plasma. The test is based on the principle of a sandwich ELISA to measure the concentration of hPG\textsubscript{80} in plasma specimens that have been anticoagulated with EDTA. Briefly, a capture monoclonal antibody raised against the C-Terminus of hPG\textsubscript{80} and that does not recognize active gastrin (gastrin-NH2) is pre-coated on the 96-well plate. hPG\textsubscript{80} present in calibrators, controls and/or specimens added to the wells bind to the immobilized capture antibody. The test plate includes calibrators...
which are used to estimate the level of hPG$_{80}$ in EDTA plasma samples. The wells are washed and a polyclonal antibody raised against the N-Terminus of hPG$_{80}$ coupled with horseradish peroxidase (HRP) is added (i.e., detection antibody), resulting in an antibody-antigen-antibody complex. After a second wash, a 3,3',5,5'-Tetramethylbenzidine (TMB) substrate solution is added to the well, producing a blue color in direct proportion to the amount of hPG$_{80}$ present in the initial sample. The Stop Solution changes the color from blue to yellow, and the wells are read at 450 nm with a microplate reader.

The analytical performances were assessed following EMEA/CHMP/EWP/192217/2009. Accordingly, there is no cross-reactivity or interference if the variation in the percentage of recovery (when compared to control (vehicle)) is equal or does not exceed 20%, and there is no change in the interpretation of the result.

Cross-reactivity was assessed using human plasma samples spiked with native hPG$_{80}$ concentrations ranging from negative to strong positive and a fixed concentration of each potential cross-reactants (i.e., KLH (Keyhole Limpet Hemocyanin), gastrin-17, Gastrin-Gly, CTFP (C-Terminus Flanking Peptide) at 2 µg/mL, CA125 (cancer antigen 125) at 2000 U/mL, CA15-3 (cancer antigen 15-3) at 100 U/mL, CEA (carcinoembryonic antigen) at 20 µg/mL or PSA (prostate specific antigen) at 210 mg/mL). For all the potential cross-reactants, the variation of the % of recovery was below 20%, showing no cross-reactivity.

Interference was also assessed using human plasma samples spiked with native hPG$_{80}$ concentrations ranging from negative to strong positive and a fixed concentration of each potentially interfering substances (i.e., SN-38 at 60 µM, 5-FU at 3 mM, triglycerides at 0.05 mg/mL, cholesterol at 25 µg/mL, conjugated bilirubin at 0.5 µg/mL or hemoglobin at 2 mg/mL). For all the potential interfering substances, the variation of the % of recovery was below 20%, showing no interference.

Based on EMEA/CHMP/EWP/192217/2009, the within-run, inter-run and inter-operator variability is defined as being the mean coefficient of variation (CV) % value of each measured control sample. It is considered acceptable when ≤20%. The CV% were determined using hPG$_{80}$-negative EDTA plasma spiked with three controls of hPG$_{80}$ at 2.5, 12.5 and 22.5 pmol/L. For all the variabilities, the CV% was below 10%, showing acceptable variabilities.

hPG$_{80}$ concentrations in pmol/L (pM) were calculated using the standard curve equation of the native hPG$_{80}$ calibrators prepared in hPG$_{80}$-negative EDTA plasmas. The limit of detection (LoD) and limit of quantification (LoQ) were calculated, as per EMEA/CHMP/EWP/192217/2009 and NCCLS EP 17-A vol.24 no.34, based on the standard deviation (CV) of the measured concentrations of $n = 74$ blanks as LoD = 3 × CV and LoQ = 10 × CV. DxPG$_{80}$ have a LoD of 1.2 pM and a LoQ of 2.3 pM.

2.3. Statistical Analyses

Comparisons between groups were performed using two-tailed Mann-Whitney $U$-test for unpaired non-parametric variables. Spearman’s rank correlation coefficient was used to measure the association between between hPG$_{80}$ levels and age. The overall survival (OS) was defined as the time from blood collection from mRCC patients with known date of death. The survival curves were constructed using the Kaplan-Meier method and compared performing a log-rank test on mRCC patients with full survival data. An optimal cutoff value of hPG$_{80}$ was defined using the function of “surv_cutpoint” in R Package “survminer”, calculating the minimal $p$-value based on the log-rank method. R software 3.6.1 (The R Foundation for Statistical Computing) was used to perform all the statistical analyses. Prism software (GraphPad, La Jolla, CA, USA) was used to create figures. The level of significance was set at $p < 0.05$.

3. Results

3.1. Characteristics of the Study Population

The demographic characteristics of the mRCC patients and control cohorts (143 mRCC patients to assess the diagnostic and prognostic values of hPG$_{80}$) are shown in Table 1.
The flowchart describing the selection of the patients for the study analysis is shown in Figure 1. The median patient age is 63 years and 74.8% were male (Table 1). The majority of the patients had metastatic clear cell renal carcinoma (77%). The median level in the mRCC cohort of plasma hPG\textsubscript{80} is 7.23 pM (Figure 2A and Table 2). The diagnostic accuracy of hPG\textsubscript{80} were evaluated in mRCC patients. While the mRCC cohort of 143 patients was divided into IMDC prognostic categories to evaluate hPG\textsubscript{80} as a prognostic factor in mRCC stage, we performed survival analysis using OS as the clinical outcome only in patients who had survival data available. For survival analysis using only hPG\textsubscript{80} levels, 47 mRCC patients were excluded (45 lost to follow-up and 2 patients with missing blood collection date) (Figure 1). For survival analysis using the IMDC score, 54 mRCC patients were excluded (45 lost to follow-up, 7 without IMDC score and 2 patients with missing blood collection date) (Figure 1). At the time of analysis, 96 and 89 patients had died from disease progression and the median OS was 19.2 and 20.1 months, for each subcohort.

Table 1. Clinical and pathological characteristics for mRCC patients and control cohorts.

| Cohorts | mRCC | Controls |
|---------|------|----------|
| N (%)  | N (%) | N (%)    |
| n = 143| n = 137| n = 252 |
| Age, years | Median (range) | 63 (41–85) | 21 (18–25) | 55 (50–80) |
| Gender | Male | 107 (74.8%) | 79 (57.7%) | 99 (39.3%) |
|        | Female | 36 (25.2%) | 58 (42.3%) | 153 (60.7%) |
| Histology | Clear cell | 110 | | |
|        | Chromophobe | 8 | | |
|        | Papillary | 14 | | |
|        | Other | 11 | | |
| Fuhrman Grade (G) | G1 | 3 | | |
|        | G2 | 45 | | |
|        | G3 | 45 | | |
|        | G4 | 32 | | |
|        | Not applicable | 0 | | |
|        | Unspecified | 18 | | |
| Sarcomatoid differentiation | Present | 16 | | |
|        | Absent | 78 | | |
|        | Unspecified | 49 | | |
| Necrosis | Present | 66 | | NA |
|        | Absent | 77 | | |
| IMDC prognostic score | Good | 28 | | |
|        | Intermediate | 81 | | |
|        | Poor | 26 | | |
|        | Unspecified | 8 | | |
| Clinical stage | I | 0 | | |
|        | II | 0 | | |
|        | III | 0 | | |
|        | IV | 143 | | |
|        | Unspecified | 0 | | |
| Total lines of systemic therapy | 0 | 24 | | |
|        | 1 | 55 | | |
|        | 2 | 30 | | |
|        | 3 | 19 | | |
|        | 4 | 8 | | |
|        | 5 or more | 7 | | |

NA: non applicable.
3.2. Diagnostic Performance of hPG80 in mRCC Patients

To determine whether hPG80 plasma levels can be used as a biomarker for mRCC diagnosis, we measured hPG80 levels in 143 mRCC patients and in the two control groups. hPG80 was detected in 94% of the RCC patients (threshold = 1.2 pM, corresponding to the limit of detection of the DxPG80 kit). Median hPG80 concentration in the mRCC cohort (median value: 7.23 pM) was significantly higher than that in the 18–25 year old control group (median value below the LoD; \( p < 0.0001 \)) (Figure 2A and Table 2). In the 50–80 year old control group, median hPG80 concentration was 1.50 pM and was also significantly lower than in mRCC patients (\( p < 0.0001 \); Figure 2A and Table 2). Although there is a significant difference in hPG80 levels between the two control groups (\( p < 0.0001 \)), in each control group there is no correlation between hPG80 levels and age (Spearman \( r = -0.13; p = 0.11 \) and Spearman \( r = -0.035; p = 0.16 \) for the 18–25 year old and 50–80 year old cohorts respectively).

Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic discriminative accuracy of hPG80 levels in mRCC patients compared to the two control groups. hPG80 levels displayed high predictive significance, with an area under the curve (AUC) value of 0.93 (95% CI: 0.91–0.96; \( p < 0.0001 \)) when compared to 18–25 year old control group, and of 0.84 (95% CI: 0.80–0.88; \( p < 0.0001 \)) when compared to 50–80 year old control group (Figure 2B,C). To further explore the diagnostic accuracy of hPG80, we used a cohort of 39 non-metastatic RCC patients (Figure S1). The demographic characteristics of the RCC patients are shown in Table S1. Consistent with the results obtained with mRCC patients, hPG80 was detected in 85% of RCC patients, median hPG80 levels was 7.36 pM (IQR: 3.05–18.23) (Figure S2 and Table S2). The diagnostic discriminative accuracy was 0.89 (95% CI: 0.82–0.95; \( p < 0.0001 \)) when compared to the 18–25 year old control group.

Table 2. hPG80 levels in mRCC patients and in control cohorts. <LoD: hPG80 levels were below the limit of detection (LoD).

| Characteristics | N  | Median (IQR), pM | Mean (SE), pM |
|-----------------|----|-----------------|--------------|
| Patients        |    |                 |              |
| mRCC            | 143| 7.23 (3.24–20.61)| 24.50 (3.75) |
| Control cohorts |    |                 |              |
| 18–25 years old | 137| <LoD            | <LoD         |
| 50–80 years old | 252| 1.5 * (0.0–3.09)| 3.82 (0.55)  |

*: Median hPG80 concentration in the 50–80 year old control group is comprised between the LoD and the limit of quantification (LoQ) (i.e., 1.2 pM and 2.3 pM).
3.3. OS for Patients with mRCC Stratified Using hPG80 Levels

We first investigated the prognostic value of hPG80 level in the absence of any other clinical parameters by stratification of patients into high and low hPG80 levels based on an optimal calculated cutoff value of hPG80 levels across all mRCC patients. The optimal cutoff value of hPG80 was obtained using the function of “surv_cutpoint” in R Package “survminer” as described in the Material and Methods section and then used for analysis of survival outcomes. We used 4.5 pM as the optimal cutoff value and patients were segregated into 2 groups above and below this value: 33 patients displayed low hPG80 levels (<4.5 pM) and 63 patients displayed high hPG80 levels (>4.5 pM). Kaplan-Meier survival analysis showed that patients with high hPG80 levels (>4.5 pM) had significantly lower OS compared to patients with low hPG80 levels (<4.5 pM) (12 versus 31.2 months, respectively; p = 0.0031) (Figure 3).

![Figure 3. Overall survival according to hPG80 levels. Kaplan-Meier analysis of OS for mRCC patients according to hPG80 levels. The p values from the log-rank test are indicated.](image)

| hPG80 < 4.5 pM | hPG80 > 4.5 pM |
|---------------|---------------|
| Median OS (months) | 31.2 | 12 |

\[ p = 0.0031 \]

3.4. hPG80 Levels According to IMDC Prognostic Group

Based on the IMDC prognostic criteria, the good, intermediate and poor prognostic categories comprised 28 (19.6%), 81 (56.6%) and 26 (18.2%) patients, respectively (Table 1). We assessed whether the IMDC prognostic score was correlated with hPG80 levels. Although the median value for hPG80 levels was numerically lower in the good-risk group (4.72 pM) in comparison to the intermediate- and poor-risk groups (7.49 pM, and 7.58 pM, respectively), our results showed that hPG80 levels were not statistically different between the IMDC prognostic groups (Figure 4 and Table 3).
Table 3. hPG80 levels according to the IMDC score in mRCC patients.

| Characteristics       | hPG80         |
|-----------------------|---------------|
|                       | N (%) Median (IQR), pM Mean (SE), pM |
| IMDC prognostic score |               |
| Good                  | 28 (20.7%) 4.72 (3.24–11.14) 20.00 (7.18) |
| Intermediate          | 81 (60.0%) 7.49 (3.73–24.55) 28.83 (5.79) |
| Poor                  | 26 (19.3%) 7.58 (2.58–19.05) 19.13 (6.11) |

3.5. OS for Patients with mRCC Stratified Using the IMDC Risk Classification

We evaluated the performance of the IMDC prognostic score and its association with OS in our cohort for all patients with survival data (Flow chart on Figure 1). In this subgroup, the good-, intermediate- and poor-risk groups comprised 11 (12.4%), 55 (61.8%) and 23 (25.8%) patients, respectively. The median OS stratified by IMDC risk classification was 38.6, 21.3 and 8 months for the good-, intermediate- and poor-risk groups, respectively (Figure 5A). A significant difference in OS was observed between the three groups \( p = 0.0076 \). The OS for patients in the poor-risk group was significantly shorter compared to patients in the good- and intermediate risk groups \( p = 0.0084 \) and \( p = 0.0360 \), respectively. The OS was also significantly shorter between patients in the intermediate-risk group and the good-risk group \( p = 0.0311 \).

3.6. OS for Patients with mRCC Stratified Using the IMDC Risk Classification and High and Low hPG80 Levels

As hPG80 levels represent an independent variable associated with OS in mRCC patients, we assessed whether the IMDC risk classification to predict OS could be improved by incorporating hPG80 levels. This model incorporates the six variables from the IMDC risk classification (score from 0 to 6) and hPG80 levels (score of 1 for patients having hPG80 levels > 4.5 pM and 0 for patients with hPG80 levels < 4.5 pM). Patients were categorized using three-level risk groups: good (score = 0–1), intermediate (score = 2–3) and poor (score ≥ 4). Using this model, the good-, intermediate- and poor-risk groups comprised 24 (27%), 47 (52.8%), and 18 (20.2%) patients, respectively. As shown in Figure 5B, the median OS stratified by this new model was 36.1, 17.9 and 7.3 months for the good-, intermediate- and poor-risk groups, respectively. A greater and significant difference in OS was observed between the three groups \( p = 0.0003 \) compared to \( p = 0.0076 \) with the IMDC risk classification.
score. Similarly to what we observed using the IMDC risk classification alone, the OS for patients in the poor-risk group was significantly shorter, compared to patients in the good- and intermediate risk groups \((p < 0.0001,\text{ and } p = 0.0279, \text{ respectively})\). There was slightly better significance achieved using \(\text{hPG}_{80}\) levels > 4.5 pM than the clinical variables in the IMDC risk classification alone while discriminating the three prognostic groups (Figure 5) and more refined discrimination for survival for patients in the intermediate-risk group and the good-risk group \((p = 0.0046)\).

\[\text{OS (months)}\]

|   | Good | Intermediate | Poor |
|---|------|--------------|------|
| Median OS | 38.6 | 21.3 | 8    |

\[\text{OS (months)}\]

|   | Good | Intermediate | Poor |
|---|------|--------------|------|
| Median OS | 36.1 | 17.9 | 7.3  |

\[\text{OS (months)}\]

|   | Good | Intermediate | Poor |
|---|------|--------------|------|
| Median OS | 36.1 | 17.9 | 7.3  |

Figure 5. Overall survival according to the IMDC score and to a model incorporating IMDC variables and \(\text{hPG}_{80}\) levels. (A). Kaplan-Meier analysis of overall survival (OS) for mRCC patients according to the IMDC risk classification (good, intermediate, poor). (B). Kaplan-Meier analysis of OS for mRCC patients with a model combining IMDC variables and \(\text{hPG}_{80}\) levels. The median OS (in months) and the \(p\) values from the log-rank test are indicated.

3.7. OS in the IMDC Intermediate-Risk Group Stratified Using \(\text{hPG}_{80}\) Levels

Based on the IMDC risk classification, patients in the intermediate-risk group harbor either one or two risk factors [14]. Consequently, there is a great variability and a lack of refinement for survival outcomes using clinical variables alone among these patients. We stratified the intermediate risk group mRCC patients by combining \(\text{hPG}_{80}\) levels with IMDC risk classification in order to analyse if it could enhance the accuracy of prognostification over IMDC classification alone. We divided the 55 mRCC patients into 2 subgroups based on the optimal calculated cutoff values of 4.5 pM described above for \(\text{hPG}_{80}\) across the mRCC patients analysed for survival outcomes. As shown in Figure 6, when patients in intermediate IMDC group were stratified into two groups based on \(\text{hPG}_{80}\) levels cutoff, the OS of patients with \(\text{hPG}_{80}\) levels > 4.5 pM were significantly lower than the one from the group with \(\text{hPG}_{80}\) levels < 4.5 pM (median OS: 17.9 versus 29.8 months; \(p = 0.0083\)).
IMDC intermediate-risk group

![Graph showing overall survival in the IMDC intermediate-risk group stratified according to hPG80 levels.](image)

**Figure 6.** Overall survival in the IMDC intermediate-risk group stratified according to hPG80 levels. Kaplan-Meier analysis of OS for mRCC patients according to the IMDC risk classification and incorporating hPG80 levels. Patients in the IMDC intermediate-risk group were divided into two groups based on the calculated cutoff value of hPG80 (4.5 pM): 18 patients displayed low hPG80 levels (<4.5 pM) and 37 patients displayed high hPG80 levels (>4.5 pM). The median OS (in months) and the \( p \) values from the log-rank test are indicated.

4. Discussion

The close relationship between hPG80 and cancer progression has been previously reported in several studies [21,24–28]. We have recently shown that tumor cells from many cell types overexpress hPG80 [17]. Its expression is related to cancer cell activity and represents a risk factor for tumor recurrence and therefore hPG80 may provide prognostic significance in metastatic stages of tumors which secrete hPG80 in measurable amounts. In this study, we demonstrate for the first time the prognostic value of hPG80 in mRCC. We also demonstrated the potential diagnostic utility of hPG80 levels in differentiating RCC and mRCC patients from healthy individuals. We established an optimal cutoff value for hPG80 (4.5 pM) in mRCC stage and were able to demonstrate that higher hPG80 levels are associated significantly with lower OS. We also explored hPG80 levels in mRCC patients for stratification into good and poor prognosis groups like the widely used IMDC model who classify patients into three risk groups (good, intermediate and poor) [14].

Our results suggest that addition of hPG80 levels to IMDC might further improve the IMDC prognostication, and also refines the heterogeneity within the intermediate-risk IMDC group. Patients in the intermediate-risk group account for 40 to 50% of all risk classes patients [32,33]. In our patient cohort, 56.6% of patients had IMDC intermediate-risk group. Study from Sella et al. has shown that patients with one-risk factor had longer OS than patients with two-risk factors, suggesting that adding new prognostic risk factors to actual IMDC risk model such as tumor and stage associated hPG80 levels could enhance the accuracy of prognostification [34]. We observed that hPG80 levels collected and measured at the time of patients progressing to metastatic stage were able to refine the
existing clinical factor based IMDC risk model prognostication of survival in patients with intermediate-risk group. In this group patients with low and high hPG80 levels were able to be identified with different survival time (median OS: 17.9 in patients with high hPG80 levels versus 29.8 months with low hPG80 levels; \( p = 0.0083 \)). In line with these data, a recent study from Kunishi et al. has shown that combining C-reactive protein (CRP) value to patients classified in the intermediate group according to the IMDC risk classification might further refine prognosis in this patient populations [35]. Altogether, although the optimal hPG80 cutoff value will need further validation in larger cohort, it supports the benefit of further studies using hPG80 levels to stratify mRCC patients and to improve the prognostic predictive power of the existing IMDC model.

Novel tissue and blood-based biomarkers including PD-L1 expression, CRP, VEGF and IL-6 serum levels have been proposed as prognostic biomarkers for mRCC [36]. Other putative biomarkers such as miRNAs, circulating DNA and metabolic biomarkers have been reported to have prognostic relevance in mRCC [36]. In addition, assessment of gene expression signatures has also shown to significantly improve the predictive power of the IMDC model and provided additional prognostic information in mRCC patients [37]. However, most of these factors were derived from retrospective studies and none of them have been validated in larger prospective studies. Currently, no specific molecular marker has been shown to improve the accuracy of existing prognostic scores which are largely based on clinical and not tumor biology associated factors (e.g., IMDC) and their use is not recommended for clinical care [38].

Cancer stem cells (CSCs) have been implicated in tumor initiation, progression, metastasis, multidrug resistance and recurrence [39]. Several lines of evidence indicates that renal CSCs are involved in driving RCC progression and treatment failure [40,41]. Previous studies have shown that hPG80 plays a major function in CSCs by regulating their survival and self-renewal ability [21]. Thereby, we can hypothesize that elevated hPG80 levels are associated with poor clinical outcome in mRCC patients by promoting CSCs survival and resistance to antiangiogenic drugs like tyrosine kinase inhibitors.

Our study presents some limitations including the use of the prospectively enrolled mRCC cohort who were retrospectively analysed and the number of patients excluded from overall survival analysis for a variety of reasons. A third of our patients were lost to follow-up and this could have biased our results. Nevertheless, hPG80 levels in mRCC biology has been well reported and the ability to measure hPG80 levels in blood provides a significant advantage for its future exploration as a prognostic or predictive biomarker.

5. Conclusions

In conclusion, we showed that elevated hPG80 levels is strongly associated with RCC and mRCC and could be a useful prognostic biomarker in these patients. If confirmed in larger datasets with longitudinal follow up in future studies, hPG80 could help risk-stratify mRCC patients into different prognostic groups and guide patient management.

Supplementary Materials: The following are available online at https://www.mdpi.com/2072-694X/13/3/375/s1, Figure S1. Flowchart of the study with RCC patients. Figure S2. Levels and performances of plasma hPG80 in patients with RCC patients. A. hPG80 concentrations in RCC patients \( (n = 39) \) compared to 18–25 \( (n = 137) \) and 50–80 \( (n = 252) \) years old control groups. One-tailed Mann-Whitney test. B to C. Diagnostic discriminative accuracies of hPG80 in RCC patients compared to control groups aged 18–25 year old (B) or 50–80 year old (C) using Receiver Operating Characteristics (ROC) curve analysis. Table S1. Clinical and pathological characteristics for RCC patients. Table S2. hPG80 levels in RCC patients.

Author Contributions: B.V., A.P., D.J., wrote the manuscript. M.K., W.T. and T.C. contributed to the first draft in manuscript writing. P.L., B.V., A.P., M.K. and D.J. analysed the data. L.P. performed the hPG80 assays. M.K., W.T., M.B., F.B., D.R. and G.G. contributed to the recruitment of patients. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of MAYO CLINIC (protocol code #11_05835 00) on 26 October 2011.

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The data presented in this study are available on request from the corresponding author.

**Conflicts of Interest:** D.J. is a co-founder of ECS-Progastrin and a senior scientific advisor of the company. A.P. is a co-founder of ECS-Progastrin and the Chief Scientific Officer of the company. All other authors: no conflict of interest.

**References**

1. Rini, B.I.; Campbell, S.C.; Escudier, B. Renal cell carcinoma. *Lancet* 2009, 373, 1119–1132. [CrossRef]
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. *CA Cancer J. Clin.* 2020, 70, 7–30. [CrossRef] [PubMed]
3. Barrisford, G.W.; Singer, E.A.; Rosner, I.L.; Linehan, W.M.; Bratslavsky, G. Familial renal cancer: Molecular genetics and surgical management. *Int. J. Surg. Oncol.* 2011, 2011, 658767. [CrossRef] [PubMed]
4. Gerlinger, M.; Rowan, A.J.; Horswell, S.; Math, M.; Larkin, J.; Endesfelder, D.; Gronroos, E.; Martinez, P.; Matthews, N.; Stewart, A.; et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. *N. Engl. J. Med.* 2012, 366, 883–892. [CrossRef] [PubMed]
5. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N. Engl. J. Med.* 2007, 356, 125–134. [CrossRef] [PubMed]
6. Beisland, C.; Johannessen, T.B.; Klepp, O.; Axcrona, U.; Torgersen, K.M.; Kowalski, J.; Solli, O.; Sandin, R.; Oldenburg, J. Overall survival in renal cell carcinoma after introduction of targeted therapies: A Norwegian population-based study. *Onco. Targets Ther.* 2017, 10, 371–385. [CrossRef] [PubMed]
7. Labriola, M.K.; Batch, K.A.; Zhu, J.; McNamara, M.A.; Harrison, M.R.; Armstrong, A.J.; George, D.J.; Zhang, T. Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma. *Clin. Genitourin. Cancer* 2019, 17, e513–e521. [CrossRef] [PubMed]
8. Brannon, A.R.; Reddy, A.; Seiler, M.; Arreola, A.; Moore, D.T.; Pruthi, R.S.; Wallen, E.M.; Nielsen, M.E.; Liu, H.; Nathanson, K.L.; et al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. *Genes Cancer* 2010, 1, 152–163. [CrossRef]
9. Beuselinck, B.; Job, S.; Becht, E.; Karadimou, A.; Verkarre, V.; Couchy, G.; Giraldo, N.; Rioux-Leclercq, N.; Molinie, V.; Sibony, M.; et al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. *Clin. Cancer Res.* 2015, 21, 1329–1339. [CrossRef]
10. Hakimi, A.A.; Ostrovnyaia, I.; Revia, B.; Schultz, N.; Chen, Y.B.; Gonen, M.; Liu, H.; Takeda, S.; Voss, M.H.; Tickoo, S.K.; et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: A report by MSKCC and the KIRC TCGA research network. *Clin. Cancer Res.* 2013, 19, 3259–3267. [CrossRef]
11. Choueiri, T.K.; Halabi, S.; Sanford, B.L.; Hahn, O.; Michaelson, M.D.; Walsh, M.K.; Feldman, D.R.; Olency, T.; Picus, J.; Small, E.J.; et al. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A012033 CABOSUN Trial. *J. Clin. Oncol.* 2017, 35, 591–597. [CrossRef] [PubMed]
12. Motzer, R.J.; Tannir, N.M.; McDermott, D.F.; Amin, S.; Choueiri, T.K.; Plimack, E.R.; Barthelemy, P.; Porta, C.; George, S.; et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* 2018, 378, 1277–1290. [CrossRef] [PubMed]
13. Rini, B.I.; Plimack, E.R.; Stus, V.; Gafanon, R.; Hawkins, R.; Nosov, D.; Pouliot, F.; Alekseev, B.; Soulieres, D.; Melichar, B.; et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. *N. Engl. J. Med.* 2019, 380, 1116–1127. [CrossRef] [PubMed]
14. Heng, D.Y.; Xie, W.; Regan, M.M.; Warren, M.A.; Golshayan, A.R.; Sahi, C.; Egl, B.J.; Ruether, J.D.; Cheng, T.; North, S.; et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study. *J. Clin. Oncol.* 2009, 27, 5794–5799. [CrossRef]
15. Jonasch, E. NCCN Guidelines Updates: Management of Metastatic Kidney Cancer. *J. Natl. Compr. Cancer Netw.* 2019, 17, 587–589. [CrossRef]
16. Motzer, R.J.; Jonasch, E.; Michaelson, M.D.; Nandagopal, L.; Gore, J.L.; George, S.; Alva, A.; Haas, N.; Harrison, M.R.; Plimack, E.R.; et al. NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. *J. Natl. Compr. Cancer Netw.* 2019, 17, 1278–1285. [CrossRef]
17. You, B.; Mercier, F.; Assent, E.; Langlois-Jacques, C.; Glehen, O.; Soule, J.; Payen, L.; Kepenekian, V.; Dupuy, M.; Belouin, F.; et al. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients. *EBioMedicine* 2019, 51, 102574. [CrossRef]
18. Rhefeld, J.F.; Zhu, X.; Norrbom, C.; Bundgaard, J.R.; Johnsen, A.H.; Nielsen, J.E.; Vikesaas, J.; Stein, J.; Dey, A.; Steiner, D.F.; et al. Prohormone convertases 1 and 2 together orchestrate the site-specific cleavages of progastrin to release gastrin-34 and gastrin-17. *Biochem. J.* 2008, 415, 35–43. [CrossRef]
19. Varro, A.; Voronina, S.; Dockray, G.J. Pathways of processing of the gastrin precursor in rat antral mucosa. J. Clin. Invest. 1995, 95, 1642–1649. [CrossRef]
20. Siddheshwar, R.K.; Gray, J.C.; Kelly, S.B. Plasma levels of progastrin but not amidated gastrin or glycine extended gastrin are elevated in patients with colorectal carcinoma. Gut 2001, 48, 47–52. [CrossRef]
21. Prieur, A.; Cappellini, M.; Habié, G.; Lefranc, M.P.; Mazard, T.; Morency, E.; Pascussi, J.M.; Flaceliere, M.; Cahuzac, N.; Vire, B.; et al. Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer. Clin. Cancer Res. 2017, 23, 5267–5280. [CrossRef] [PubMed]
22. Koh, T.J.; Chen, D. Gastrin as a growth factor in the gastrointestinal tract. Regul. Pept. 2000, 93, 37–44. [CrossRef]
23. Xu, Q.; Krause, M.; Samoylenko, A.; Vainio, S. Wnt Signaling in Renal Cell Carcinoma. Cancers 2016, 8, 57. [CrossRef] [PubMed]
24. Hollande, F.; Lee, D.J.; Choquet, A.; Roche, S.; Baldwin, G.S. Adherens junctions and tight junctions are regulated via different pathways by progastrin in epithelial cells. J. Cell Sci. 2003, 116, 1187–1197. [CrossRef] [PubMed]
25. Singh, P.; Owlia, A.; Varro, A.; Dai, B.; Rajaraman, S.; Wood, T. Gastrin gene expression is required for the proliferation and tumorigenicity of human colon cancer cells. Cancer Res. 1996, 56, 4111–4115. [PubMed]
26. Wu, H.; Owlia, A.; Singh, P. Precursor peptide progastrin(1-80) reduces apoptosis of intestinal epithelial cells and upregulates cytochrome c oxidase Vb levels and synthesis of ATP. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285, G1097–G1110. [CrossRef]
27. Giraud, J.; Failia, L.M.; Pascussi, J.M.; Lagerqvist, E.L.; Ollier, J.; Finetti, P.; Bertucci, F.; Ya, C.; Gasmì, I.; Bourgaux, J.F.; et al. Autocrine Secretion of Progastrin Promotes the Survival and Self-Renewal of Colon Cancer Stem-like Cells. Cancer Res. 2016, 76, 3618–3628. [CrossRef] [PubMed]
28. Najib, S.; Kowalski-Chauvel, A.; Do, C.; Roche, S.; Cohen-Jonathan-Moyal, E.; Seva, C. Progastrin a new pro-angiogenic factor in colorectal cancer. Oncogene 2015, 34, 3120–3130. [CrossRef]
29. Du, M.; Giridhar, K.V.; Tian, Y.; Tschannen, M.R.; Zhu, J.; Huang, C.C.; Kiliari, D.; Kohli, M.; Wang, L. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget 2017, 8, 63703–63714. [CrossRef]
30. Giridhar, K.V.; Sosa, C.P.; Hillman, D.W.; Sanhueza, C.; Dalpiaz, C.L.; Costello, B.A.; Quevedo, F.J.; Ptit, H.C.; Dronca, R.S.; Ertz, D.; et al. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int. J. Mol. Sci. 2017, 18, 2326. [CrossRef]
31. White, M.C.; Holman, D.M.; Boehm, J.E.; Peipins, L.A.; Grossman, M.; Henley, S.J. Age and cancer risk: A potentially modifiable relationship. Am. J. Prev. Med. 2014, 46, S7–S15. [CrossRef] [PubMed]
32. Shinohara, N.; Obara, W.; Tatsugami, K.; Naito, S.; Kamba, T.; Takahashi, M.; Murai, S.; Abe, T.; Oba, K.; Naito, S. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci. 2015, 106, 618–626. [CrossRef] [PubMed]
33. Shimizu, Y.; Iguchi, T.; Tamada, S.; Yasuda, S.; Kato, M.; Ninomiya, N.; Yamasaki, T.; Nakatani, T. Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer. Mol. Clin. Oncol. 2018, 8, 791–796. [CrossRef] [PubMed]
34. Sella, A.; Michaelson, M.D.; Matczak, E.; Simantov, R.; Lin, X.; Figlin, R.A. Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib. Clin. Genitourin. Cancer 2017, 15, 291–299. [CrossRef] [PubMed]
35. Beuselinck, B.; Vano, Y.A.; Oudard, S.; Wolter, P.; De Smet, R.; Depoorter, L.; Teghom, C.; Karadimou, A.; Zucman-Rossi, J.; et al. Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma. Int. J. Mol. Sci. 2017, 18, 2326. [CrossRef]
36. Shimizu, Y.; Iguchi, T.; Tamada, S.; Yasuda, S.; Kato, M.; Ninomiya, N.; Yamasaki, T.; Nakatani, T. Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer. Mol. Clin. Oncol. 2018, 8, 791–796. [CrossRef] [PubMed]
37. Selin, L.K. Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist 2017, 22, 286–292. [CrossRef] [PubMed]
38. Escudier, B.; Porta, C.; Schmidinger, M.; Rioux-Leclercq, N.; Bex, A.; Khoo, V.; Grunwald, V.; Gillessen, S.; Horwich, A.; ESMO Guidelines Committee. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-updagger. Clin. Cancer Res. 2017, 23, 790–803. [CrossRef] [PubMed]
39. Atashzar, M.R.; Baharlou, R.; Karami, J.; Abdollahi, H.; Rezaei, R.; Pourramezan, F.; Zoljalali Moghaddam, S.H. Cancer stem cells: A review from origin to therapeutic implications. J. Cell Sci. 2020, 235, 790–803. [CrossRef]
40. Bussolati, B.; Dekel, B.; Azzaron, B.; Camussi, G. Human renal cancer stem cells. Cancer Lett. 2013, 338, 141–146. [CrossRef]
41. Varna, M.; Gapihan, G.; Feugeas, J.P.; Ratajczak, P.; Tan, S.; Ferreira, I.; Leboeuf, C.; Setterblad, N.; Duval, A.; Verine, J.; et al. Stem cells increase in numbers in perinecrotic areas in human renal cancer. Clin. Cancer Res. 2015, 21, 916–924. [CrossRef] [PubMed]